Mohamed O. Radwan is a post-doctoral fellow at Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Kumamoto University, Japan. His home institute is the National Research Centre, Egypt. He obtained his Ph.D. from Kumamoto University in 2016. He has experience in the development of anti-cancer and anti-HIV-1 synthetic and semi-synthetic chemotherapeutic agents. His main research objective is the development of tyrosine kinase inhibitors (TKI) as anti-cancer chemotherapeutics and the generation of A3G/Vif axis inhibitors to act as anti-HIV1 drugs.